Innovent Biologics expand strategic partnership with Eli Lilly
Category: #health  By Mateen Dalal  Date: 2022-03-28
  • share
  • Twitter
  • Facebook
  • LinkedIn

Innovent Biologics expand strategic partnership with Eli Lilly

Innovent Biologics, Inc., a biopharmaceutical firm dedicated to developing, commercializing, and manufacturing high-quality medicines, has extended its partnership with Eli Lilly and Company given to their shared commitment to bringing innovative medicines to benefit Chinese patients.

Under the agreement, Innovent will be procuring the exclusive commercialization rights to promote, import, distribute, market, and detail Retsevmo® (selpercatinib) and Cyramza® (ramucirumab) once it gets permitted in Mainland China.

It will also offer a right of negotiation to Innovent for possible future Pirtobrutinib commercialization in China.

For the unversed, Cyramza® (ramucirumab) is said to be the first U.S. FDA (Food and Drug Administration) permitted treatment for patients with or metastatic gastric, advanced or gastroesophageal junction (GEJ) adenocarcinoma with disease progression on or amid preceding chemotherapy.

In China, the combination of Cyramza® (ramucirumab) and paclitaxel was approved by NMPA (National Medical Products Administration) for treating patients with advanced or metastatic GEJ adenocarcinoma in March 2022, making it the very first drug authorized for the second-line treatment of advanced gastric cancer in China.

Gastric and liver cancer are the third and fifth most significant cancers in terms of prevalence, with a total of 900,000 new cases every year in China.

Mostly the patients encounter disease progression on or after the first-line treatment. There is an unmet medical requirement for new treatment options to enhance outcomes in these patients.

Under this agreement, Innovent will have exclusive commercialization rights for both Cyramza® and Retsevmo®, once authorized in China. Innovent will be entirely responsible for the importation, pricing, marketing, distribution, and detailing of the two products.

Innovent, with an additional extended oncology product portfolio, wishes to use its qualified oncology commercial team to influence its broad commercial coverage in pharmacies and hospitals at several tiers for making these innovative treatment options available to cancer patients in China.

Source credit - https://www.prnewswire.com/news-releases/innovent-and-lilly-expand-strategic-partnership-in-oncology-301511330.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Saepio, Echoworx partner to deliver Next-Gen security solutions
Saepio, Echoworx partner to deliver Next-Gen security solutions
By Mateen Dalal

Saepio Information Security, a market leader in statement encryption and cloud-based email, has reportedly announced its collaboration with Echoworx to offer next-generation safe delivery of sensitive and secret information to any email receiver...

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...